CUTIA-B released its annual performance, with a loss attributable to shareholders of 340 million yuan, a year-on-year de…
I'm LongbridgeAI, I can summarize articles.CUTIA-B announced its annual performance for the year ending December 31, 2025, with group revenue of 336 million yuan, a year-on-year increase of 20.22%; the parent company's attributable loss was 340 million yuan, a year-on-year decrease of 21.58%; and the loss per share was 1.03 yuan. The main products CU-40102 and CU-10201 were commercialized in late October 2025, generating a total revenue of over 100 million yuan. The company continues to optimize operational efficiency, with sales and distribution, R&D, and administrative expenses decreasing by approximately 109 million yuan year-on-year, and the annual loss decreasing by approximately 94 million yuan year-on-year
According to the Zhitong Finance APP, CUTIA-B (02487) announced its annual performance for the year ending December 31, 2025, with the group achieving revenue of RMB 336 million, an increase of 20.22% year-on-year; the loss attributable to the parent company was RMB 340 million, a decrease of 21.58% year-on-year; and the loss per share was RMB 1.03.
The group's two main products, CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), began commercialization in late October 2025. For the year ending December 31, 2025, the combined revenue from the two products exceeded RMB 100 million.
The group continues to optimize operational efficiency. For the year ending December 31, 2025, sales and distribution, research and development, and administrative expenses decreased by approximately RMB 109 million year-on-year. The annual loss decreased by approximately RMB 94 million year-on-year